Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes

The ADJUVANT study reported the comparative superiority of adjuvant gefitinib over chemotherapy in disease-free survival of resected EGFR-mutant stage II–IIIA non-small cell lung cancer (NSCLC). However, not all patients experienced favorable clinical outcomes with tyrosine kinase inhibitors (TKI),...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Si-Yang, Bao, Hua, Wang, Qun, Mao, Wei-Min, Chen, Yedan, Tong, Xiaoling, Xu, Song-Tao, Wu, Lin, Wei, Yu-Cheng, Liu, Yong-Yu, Chen, Chun, Cheng, Ying, Yin, Rong, Yang, Fan, Ren, Sheng-Xiang, Li, Xiao-Fei, Li, Jian, Huang, Cheng, Liu, Zhi-Dong, Xu, Shun, Chen, Ke-Neng, Xu, Shi-Dong, Liu, Lun-Xu, Yu, Ping, Wang, Bu-Hai, Ma, Hai-Tao, Yan, Hong-Hong, Dong, Song, Zhang, Xu-Chao, Su, Jian, Yang, Jin-Ji, Yang, Xue-Ning, Zhou, Qing, Wu, Xue, Shao, Yang, Zhong, Wen-Zhao, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575965/
https://www.ncbi.nlm.nih.gov/pubmed/34750392
http://dx.doi.org/10.1038/s41467-021-26806-7

Ejemplares similares

Ejemplares similares